Suppr超能文献

全喉切除术或全下咽-喉-食管切除术后放疗后甲状腺切除范围及甲状腺功能

Extent of thyroid resection and thyroid function after postoperative radiotherapy following total laryngectomy or total pharyngo-laryngo-esophagectomy.

作者信息

Kojima Rio, Tsukahara Kiyoaki, Motohashi Ray, Okada Takuro, Yatomi Masanori, Katsube Yasuaki, Takeda Atsuo, Agata Ayumi, Ogawa Yasuo

机构信息

Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.

出版信息

Int J Clin Oncol. 2017 Jun;22(3):438-441. doi: 10.1007/s10147-016-1082-x. Epub 2017 Jan 4.

Abstract

OBJECTIVE

Concurrent chemoradiotherapy (CCRT) is often performed after total pharyngo-laryngo-esophagectomy (TPLE) or total laryngectomy (TL). Hypothyroidism is one of the side-effects of CCRT. The objective of this study was to ascertain the timing of onset and severity of latent hypothyroidism among patients who underwent radiotherapy (RT) or CCRT after TPLE or TL, using thyroid-stimulating hormone (TSH) as a biomarker, and to explore methods of preventing its development.

METHODS

Participants comprised 21 patients who underwent these treatments at Tokyo Medical University Hachioji Medical Center between May 2009 and December 2013. TSH, free thyroxine 3, and free thyroxine 4 levels were used as indicators of thyroid function, and thyroid hormone was administered for TSH levels ≥15 µU/mL.

RESULTS

Post-radiotherapeutic TSH levels in 17 of the 21 patients (81%) were not within the reference value, and 10 (48%) required thyroid hormone therapy. Pharmacotherapy was initiated within 1 year in 5 of these 10 patients (50%), and between 1 and 3 years in the remaining 5 patients. No patient who did not undergo thyroidectomy required hormone therapy. Early evaluation of thyroid function appears important when postoperative RT, including CCRT, is performed in combination with TPLE or TL.

CONCLUSION

Our study suggested that postoperative CCRT or RT after TPLE or TL, especially hemithyroidectomy, carries a high risk for hypothyroidism.

摘要

目的

同步放化疗(CCRT)常在全下咽-喉-食管切除术(TPLE)或全喉切除术(TL)后进行。甲状腺功能减退是CCRT的副作用之一。本研究的目的是确定以促甲状腺激素(TSH)作为生物标志物,在接受TPLE或TL后进行放疗(RT)或CCRT的患者中,隐匿性甲状腺功能减退的发病时间和严重程度,并探索预防其发生的方法。

方法

研究对象包括2009年5月至2013年12月在东京医科大学八王子医疗中心接受这些治疗的21例患者。TSH、游离三碘甲状腺原氨酸和游离甲状腺素4水平用作甲状腺功能指标,TSH水平≥15µU/mL时给予甲状腺激素。

结果

21例患者中有17例(81%)放疗后的TSH水平不在参考值范围内,10例(48%)需要甲状腺激素治疗。这10例患者中有5例(50%)在1年内开始药物治疗,其余5例在1至3年内开始治疗。未接受甲状腺切除术的患者均无需激素治疗。当联合TPLE或TL进行包括CCRT在内的术后放疗时,早期评估甲状腺功能似乎很重要。

结论

我们的研究表明,TPLE或TL后进行术后CCRT或RT,尤其是半甲状腺切除术,发生甲状腺功能减退的风险很高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验